Skip to content
Still Well After 40
Menu

TB-500 vs BPC-157 (and the four other HHS peptides)

What the human research says about each of the six peptides in the October 2026 HHS policy, and what the policy still doesn't allow.

By Adam Greene · · 12 min read

Illustration of glowing molecule models labeled BPC-157, TB-500, MOTS-c, Semax, Epitalon and KPV on a dark blue background
Illustration.

Related: Peptides after 40 (updated Oct 30, 2026)

HHS’s Oct 30, 2026 interim policy lets state-licensed 503A pharmacies compound six peptides (BPC-157, TB-500, MOTS-c, Semax, Epitalon and KPV) for a named patient with a prescription, as long as ten conditions are met. It isn’t FDA approval, and it doesn’t cover research-use-only vials or a BPC-157 and TB-500 blend. For most of these six, the human evidence is thin or missing.

I already walked through the legal side in my peptides essay, so if your question is whether BPC-157 is legal, start there. This page is the scorecard, with one card per peptide comparing what it’s sold for against what has actually been studied in people.

What HHS changed and what it didn’t

The policy is called the “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.” It ran in the Federal Register on Oct 30, 2026 (91 FR 68526, document 2026-22192). In plain English, HHS says it won’t take action against a state-licensed pharmacy or a licensed physician that compounds one of these six for an individual patient with a prescription, as long as every one of the ten conditions is met.

Two of those conditions matter most to regular people. Each product can contain only one peptide. The raw ingredient has to come from an FDA-registered manufacturer and arrive with a certificate of analysis that meets FDA’s testing standard.

The Federal Register notice calls this a draft policy and says it isn’t binding on HHS or the public. HHS also says it can revisit the policy if a safety or quality problem shows up.

What it didn’t do. It isn’t FDA approval. None of the six is on the 503A bulks list, which still takes an FDA rule with its own comment period, and the policy only lasts until each peptide is dealt with in a final rule. Research-use-only vials sold online still aren’t covered. A pharmacy can’t put BPC-157 and TB-500 in the same vial, so the “Wolverine stack” isn’t available as one product. Sport rules didn’t move either. WADA still bans BPC-157 and TB-500 at all times.

Comments closed Nov 13, 2026, at 11:59 PM ET (10:59 PM Central). HHS received 289 of them on regulations.gov under docket HHS-OASH-2026-0496. It hasn’t issued a final policy or said what comes next, so the Oct 30 draft policy still stands for now.

Where I’m coming from

I’ve used four of the six. BPC-157 and TB-500 both helped me, and I took them before I fully understood the risks. Semax has been shockingly great for my ADHD. MOTS-c didn’t do anything I could notice. I’ve never touched Epitalon or KPV, so those two cards are evidence only.

I’m not a doctor, and I’m not telling you to take any of this. I’ll be straight with you, though. Some of what I’ve taken came from the gray market, and I’m still taking Semax. It’s helped me, and I’m not going to pretend it didn’t. That doesn’t make it a miracle, and it doesn’t mean it’ll do the same for you.

If you decide to try peptides anyway, pay for real third-party testing. Don’t just trust the certificate the manufacturer sends you, because those are easy to fake. Some people online try to check gray-market test results against each other, and they’re worth a look. That won’t guarantee what’s in the vial, but it can cut down the risk you’re already taking.

If you’ve got joint or tendon pain and you’re curious about BPC-157, ask your doctor about a prescription. That way it comes from a source that has to follow real testing rules.

The six at a glance

Peptide What it’s sold for Best human evidence Route allowed under the HHS policy Covered form Banned in sport?
BPC-157 Tendon, ligament, muscle and gut healing 3 small uncontrolled studies, 30 people, very low certainty Injection (under the skin or into muscle), oral, topical Acetate Yes, WADA S0
TB-500 Tissue repair and recovery None for TB-500 itself Injection (under the skin or into muscle) only Acetate Yes, WADA S2
MOTS-c Metabolism and exercise capacity No completed trial; first randomized trial still recruiting Injection (under the skin or into muscle) Acetate Yes, prohibited at all times per USADA
Semax Focus and stroke recovery Russian stroke studies plus two small pilots in healthy people Nasal only Free base Check Global DRO
Epitalon Anti-aging and telomeres Small biomarker studies, no solid trial Injection (under the skin or into muscle), in intermittent courses Acetate Check Global DRO
KPV Gut and skin inflammation None in humans Topical or oral only Acetate Check Global DRO

TB-500 vs BPC-157

BPC-157 TB-500
What it is Synthetic 15-amino-acid peptide sold for soft-tissue and gut recovery Synthetic seven-amino-acid fragment of thymosin beta-4
Human evidence 3 small uncontrolled studies, 30 people total, very low certainty No published human studies of TB-500 itself
Allowed routes Under the skin, into muscle, oral, topical Under the skin or into muscle only
Compounded together? Not under this policy Not under this policy

Nobody has run a head-to-head human trial of TB-500 vs BPC-157. So the comparison comes down to how much each one has been studied on its own, and BPC-157 is ahead, even though its lead is three small studies. People who use them together call it the Wolverine stack, and a pharmacy can’t compound that as one product under this policy.

BPC-157

What it’s sold for: Healing tendons, ligaments, muscle and the gut.

Best human evidence: Thin. A systematic review published Oct 8, 2026 in Acta Orthopaedica Belgica (Poolton and colleagues) found three human studies with 30 people total. The biggest was 16 people who got knee injections for knee pain. All three reported most people improved with no treatment-related side effects. The reviewers still rated every study poor quality and the certainty very low. A hamstring trial (NCT07437547) is recruiting now, and a rotator cuff repair trial (NCT07803250) hasn’t started yet.

Known side effects: The small studies reported none tied to treatment. Thirty people can’t tell you much about safety, though. Any injected product carries infection and contamination risk.

Route allowed: BPC-157 acetate as an injection under the skin or into muscle, or in oral or topical form. Oral versions need pharmacy proof that the formula gets absorbed in humans.

Legal status: Covered by the interim HHS policy for compounding with a prescription. It isn’t FDA approved and isn’t on the 503A bulks list. WADA lists it under S0, banned at all times.

My experience: BPC-157 is the most helpful medication I’ve ever taken. I tore my shoulder, and BPC-157 along with slow strengthening helped my recovery. One of my goals is to do a pull-up again, and I’m working toward it.

TB-500

What it’s sold for: Tissue repair and recovery. It’s often marketed as if it were thymosin beta-4.

Best human evidence: There are no published human studies of TB-500 itself. In its July 2026 briefing, FDA found no information on TB-500 given to humans. TB-500 is a short synthetic fragment of thymosin beta-4. HHS points to the full protein’s human safety record, though results on the full protein don’t carry over to a fragment automatically.

Known side effects: Unknown in humans. FDA raised aggregation, where peptides clump together, as a quality concern. Any injected product carries infection and contamination risk.

Route allowed: TB-500 acetate, injected under the skin or into muscle only.

Legal status: Same interim HHS path as BPC-157. It isn’t FDA approved and isn’t on the 503A bulks list. WADA lists it under S2, banned at all times.

My experience: TB-500 helped me too. I’m aware that puts me in an odd spot, since it’s the one with zero human studies behind it.

The other four

MOTS-c

What it’s sold for: Metabolism and exercise capacity. It also gets a lot of anti-aging marketing.

Best human evidence: There’s no completed human trial of MOTS-c. Your mitochondria make it on their own, and exercise raises MOTS-c levels in people. In mice, MOTS-c treatment improved physical performance. The first randomized, placebo-controlled trial of MOTS-c itself (MOTS-MET, NCT07505745), in adults with prediabetes and overweight or obesity, is recruiting now with primary completion estimated for February 2027.

Known side effects: USADA says nobody knows when it’s safe to use. People who bought it online have reported a faster heart rate or palpitations, injection site irritation, insomnia, immune reactions and fever.

Route allowed: MOTS-c acetate, injected under the skin or into muscle.

Legal status: Covered by the interim HHS policy. It isn’t FDA approved. USADA says MOTS-c is prohibited at all times under WADA’s metabolic modulators class.

My experience: I tried it and didn’t notice any clear effect.

Semax

What it’s sold for: Focus, plus stroke recovery in Russia, where it was developed.

Best human evidence: Semax has more published human use than the other five, mostly from Russian stroke research. In a 1997 study, 30 stroke patients who got Semax on top of standard care recovered some neurological function faster than 80 patients on standard care alone. A 2018 study of 110 stroke rehab patients found it raised blood BDNF levels and improved daily-function scores. The Alzheimer’s Drug Discovery Foundation found little evidence it helps cognition in healthy people. None of the studies I found looked at ADHD.

Known side effects: The ADDF report lists discoloration inside the nose in about 10% of patients and a blood sugar rise in about 7.4% of diabetic patients. There’s little human data beyond that.

Route allowed: Semax free base, nasal use only.

Legal status: Covered by the interim HHS policy for nasal use. It isn’t FDA approved. For sport, check Global DRO.

My experience: Semax has been shockingly great for me. I have pretty bad ADHD, and my ability to focus and get through tasks has grown exponentially since I started. I’m still taking it.

Epitalon

What it’s sold for: Anti-aging and telomeres.

Best human evidence: There’s no solid human trial of epitalon. It’s a synthetic four-amino-acid peptide modeled on epithalamin, a separate pineal gland extract, so epithalamin studies don’t count for it. An October 2026 review in the International Journal of Molecular Sciences (Jain et al.) found only small biomarker studies and one older controlled study in retinitis pigmentosa, an inherited eye disease. No adequately powered randomized trial has shown it works.

Known side effects: Poorly understood. The same review calls long-term safety data inadequate. Any injected product carries infection and contamination risk.

Route allowed: Epitalon acetate, injected under the skin or into muscle, in intermittent courses.

Legal status: Covered by the interim HHS policy. It isn’t FDA approved. For sport, check Global DRO.

KPV

What it’s sold for: Inflammation, mostly in the gut. It also shows up in skin products.

Best human evidence: None in humans. In its July 2026 briefing, FDA found no clinical studies or human exposure data for KPV. It’s a three-amino-acid fragment of a hormone called alpha-MSH.

Known side effects: Unknown in humans. FDA said there wasn’t enough data to rule out immune reactions or aggregation.

Route allowed: KPV acetate, topical or oral only. Injectable KPV isn’t covered.

Legal status: Covered by the interim HHS policy for those routes. It isn’t FDA approved. For sport, check Global DRO.

How to read this scorecard

The best evidence would be a finished, published randomized trial, and none of the six has one for the uses people buy them for. Semax and BPC-157 have small human studies. Epitalon barely does. MOTS-c mostly has animal work, and TB-500 and KPV have nothing in humans. A lot of that gap comes down to nobody paying for trials, which I covered in the essay. Before you trust any certificate of analysis, read Nobody is testing your vial. I don’t sell any of these and there are no affiliate links here (how we choose products).

Frequently asked questions

What’s the difference between TB-500 and BPC-157?

They’re different molecules with different evidence. BPC-157 has three small uncontrolled human studies with about 30 people. TB-500, a short fragment of thymosin beta-4, has no published human studies of its own. Under the interim HHS policy, a pharmacy can compound each one as a single-ingredient product with a prescription. A blend of the two isn’t covered.

Partly. Since Oct 30, 2026, HHS says it won’t take action against 503A pharmacies or physicians that compound BPC-157 acetate for a patient with a prescription, if the policy’s ten conditions are met. That isn’t FDA approval, and research-use-only vials sold online still aren’t covered. My peptides essay walks through the details.

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide made by your mitochondria, studied for metabolism and exercise capacity. There’s no completed human trial of MOTS-c itself. The first randomized trial, in adults with prediabetes, is recruiting now with results expected no sooner than 2027.

What are the benefits of Semax?

Semax has been studied mainly in Russia for stroke, where small studies found faster recovery and higher BDNF levels when it was added to standard care. The Alzheimer’s Drug Discovery Foundation found little evidence it improves cognition in healthy people. I’ve had a great experience with it for ADHD focus, but no study I found looked at ADHD.

Can I get the Wolverine stack compounded?

Not as one product. The HHS policy only covers compounded products with a single active ingredient, so BPC-157 and TB-500 can’t go in the same vial. A pharmacy can compound each one separately with a prescription.

Did the FDA approve these six peptides?

No. The HHS policy is enforcement discretion, which means HHS won’t take action against pharmacies that compound these six under its conditions. None of them is FDA approved, and none is on the 503A bulks list. Getting on that list still takes an FDA rule with its own public comment period.

No. The policy covers compounding by state-licensed pharmacies and licensed physicians for a patient with a prescription. HHS said it’s meant to discourage the widespread use of research-use-only peptides from foreign manufacturers. Vials sold online as “for research use only” aren’t covered by it.

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a seven-amino-acid synthetic fragment of thymosin beta-4, which is a much larger protein. Research on the full protein doesn’t automatically apply to the fragment. FDA found no published human studies of TB-500 itself.

When did public comments on the HHS peptide policy close?

Nov 13, 2026, at 11:59 PM ET, which was 10:59 PM Central. HHS received 289 comments on docket HHS-OASH-2026-0496. No final policy has been issued yet, so the Oct 30 draft policy still stands for now.

Bottom line

HHS opened a pharmacy door for six peptides, which is a real change from buying research vials online. None of this is FDA approval, and the evidence is where it was before the policy. BPC-157 has a handful of small studies and Semax has its Russian stroke research. The other four have little or nothing in humans. BPC-157 and Semax have both done a lot for me, and I’m not going to pretend otherwise. If you’re thinking about any of these, bring your doctor in and get it from a pharmacy that has to meet the testing rules.

General information, not medical or legal advice. I’m not a doctor, and you should talk with a qualified clinician who knows your history before starting or changing any medication or supplement. See our full disclaimer.

Sources

  1. 1.HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, notice of availability. Federal Register, Oct 30, 2026, 91 FR 68526, doc 2026-22192.
  2. 2.HHS, full policy text with Appendix A and Appendix B.
  3. 3.Regulations.gov, comment page, docket HHS-OASH-2026-0496.
  4. 4.Poolton, Minett, Kazmi. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review. Acta Orthopaedica Belgica, Oct 8, 2026.
  5. 5.ClinicalTrials.gov: NCT07437547 (BPC-157, hamstring strain), NCT07803250 (BPC-157, rotator cuff repair), NCT02637284 (PCO-02 safety trial).
  6. 6.FDA, Pharmacy Compounding Advisory Committee briefing document, TB-500, July 23-24, 2026.
  7. 7.ClinicalTrials.gov: NCT07505745, MOTS-MET.
  8. 8.USADA, What is the MOTS-c peptide?
  9. 9.Gusev et al., Semax in acute ischemic stroke, 1997 (Russian). PubMed 11517472.
  10. 10.Gusev et al., Semax at different stages of ischemic stroke, 2018 (Russian). PubMed 29798983.
  11. 11.Alzheimer's Drug Discovery Foundation, Cognitive Vitality report: Semax.
  12. 12.Jain et al., Epitalon and Epithalamin: A Narrative Review. Int J Mol Sci, Oct 8, 2026. PubMed 42884164.
  13. 13.FDA, Pharmacy Compounding Advisory Committee briefing document, KPV, July 23-24, 2026.
  14. 14.USADA, Athlete Advisory: What's New on the 2027 WADA Prohibited List?

Links checked November 9, 2026. Figures are quoted from the sources above; associations in observational studies don't prove cause and effect.

Keep reading

Peptides · 12 min read

Peptides After 40: Why Nobody's Paying to Find Out

Is BPC-157 legal now? What the new HHS policy does and doesn't make legal for BPC-157, TB-500 and four others, why the evidence is still thin, and why nobody is testing your vial.

The Still Well letter

Plain-English notes on strength, energy, recovery, and staying capable after 40. No hype, no spam. The list launches soon — until then, reach us at [email protected].

Signup isn't open yet. We'll turn this on when the email list is ready.